DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: LUNESTA

Summary for Tradename: LUNESTA

Patents:1
Applicants:1
NDAs:1
Suppliers: see list11
2013 Sales:$851,791,000
drug
patent expirations by year for
 LUNESTA

Clinical Trials for: LUNESTA

Efficacy & Safety of Eszopiclone (Lunesta) in Nursing Home Patients
Status: Completed Condition: Poor Quality Sleep

The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia
Status: Completed Condition: Depression; Anxiety; Insomnia

Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban
Status: Terminated Condition: Insomnia; Nicotine Dependence

Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder
Status: Completed Condition: Post-Traumatic Stress Disorders

Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Status: Completed Condition: Parkinson's Disease; Insomnia

Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Status: Completed Condition: Insomnia; Attention Deficit Hyperactivity Disorder

Eszopiclone in the Treatment of Insomnia and Fibromyalgia
Status: Completed Condition: Fibromyalgia; Insomnia

Eszopiclone for the Treatment of Posttraumatic Stress Disorder
Status: Recruiting Condition: Posttraumatic Stress Disorders

Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
Status: Completed Condition: Insomnia; Generalized Anxiety Disorder

A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)
Status: Completed Condition: Insomnia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476Dec 15, 2004RXNo<disabled><disabled>
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476Dec 15, 2004RXNo<disabled><disabled>
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476Dec 15, 2004RXNo6,444,673*PED<disabled>Y<disabled>
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476Dec 15, 2004RXYes<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LUNESTA

Drugname Dosage Strength RLD Submissiondate
eszopicloneTablets1 mg, 2 mg and 3 mgLunesta12/15/2008

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc